Brokers Offer Predictions for NTLA FY2030 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Brookline Capital Management issued their FY2030 earnings estimates for shares of Intellia Therapeutics in a note issued to investors on Tuesday, January 27th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of $75.05 for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. The business had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The business’s revenue was up 51.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.34) earnings per share.

Several other analysts have also recently commented on the company. Royal Bank Of Canada reduced their price target on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating for the company in a report on Friday, November 7th. Evercore ISI set a $8.00 price objective on Intellia Therapeutics and gave the stock an “in-line” rating in a research report on Tuesday, November 11th. Sanford C. Bernstein set a $14.50 target price on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Finally, Robert W. Baird set a $7.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday. Nine analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and a consensus price target of $18.00.

Intellia Therapeutics Trading Up 0.6%

Shares of NTLA opened at $13.90 on Wednesday. The stock’s 50 day moving average is $10.34 and its two-hundred day moving average is $12.95. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25. The firm has a market capitalization of $1.61 billion, a PE ratio of -3.26 and a beta of 2.05.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the sale, the executive vice president directly owned 98,533 shares in the company, valued at $907,488.93. This trade represents a 7.95% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 53,051 shares of company stock worth $488,600. 3.10% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CWM LLC lifted its stake in shares of Intellia Therapeutics by 4.7% during the third quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after buying an additional 856 shares during the period. Comerica Bank lifted its stake in shares of Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after purchasing an additional 927 shares during the last quarter. Cyndeo Wealth Partners LLC grew its position in shares of Intellia Therapeutics by 9.3% in the third quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after purchasing an additional 995 shares during the period. Finally, Interchange Capital Partners LLC increased its stake in Intellia Therapeutics by 9.7% in the third quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after purchasing an additional 1,030 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.